Demonstrated success with our collaborations
Evara Health’s efforts resulted in a remarkable 52% and 72% increase in CRC screening rates over 1 year and 4 years, respectively.1
The CRC screening rate for NCH grew by 23% from 2018 to 2022.1
“Our system is happy we made this choice because it will set up our patients for success at a time when staffing resources are severely curtailed.”
The CRC screening rate for Sanitas Medical Center grew from 34% in 2018 to 72% by 2022.1

- Our Patient Navigation Program (in English and Spanish) can help improve screening rates (observed 22% increase
1* ) by providing reminders and resources to help patients successfully complete screening - Dedicated Customer Care Center to get information related to orders, Health Insurance Portability and Accountability Act (HIPAA) concerns, or other screening questions
- We have extensive resources to inform, educate, and guide your providers and patients. Download our example screening options flyer in English or Spanish.
- Based on internal data from February 11, 2022, to September 5, 2022, that compared eligible patients who received outreach from the patient navigation program with a small control sample that did not in order to evaluate program effectiveness.
4
Successful strategies to improve CRC screening
Connect with us to learn how we can support your CRC screening goals
Footnote and reference
- Compared with a small control sample of patients who do not receive outreach from the Patient Navigation Program for evaluating program effectiveness.1
- Data on file for patient navigation claims data. Customer Experience. 2022. Exact Sciences Corporation. Madison, WI.
Important Information about the Cologuard products
Indications for Use
The Cologuard® and Cologuard Plus™ tests are intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. A positive result may indicate the presence of colorectal cancer (CRC) or advanced adenoma (AA)/advanced precancerous lesions (APL) and should be followed by a colonoscopy. The Cologuard test and Cologuard Plus test are indicated to screen adults of either sex, 45 years or older, who are at average risk for CRC. These tests are not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals.
Contraindications
The Cologuard products are not for high-risk individuals, including patients who have the following:
- a personal history of colorectal cancer and adenomas
- a positive result from another colorectal cancer screening method within a test recommended timeframe
- have been diagnosed with a condition associated with high risk for colorectal cancer such as IBD, chronic ulcerative colitis, Crohn’s disease
- have a family history of colorectal cancer, or certain hereditary syndromes
Warnings and Precautions
All positive results should be referred to colonoscopy.
The Cologuard products may produce false positive and false negative results. A false positive result occurs when a result is positive, even though a colonoscopy will not find CRC or APL. A false negative result occurs when a result is negative, even when a colonoscopy identifies APL or CRC.
A negative result does not guarantee the absence of colorectal cancer or advanced adenoma. Following a negative result, patients should continue participating in a screening program at an interval and with a method appropriate for the individual patient. Performance when used for repeat testing has not been established.
Refer to the Cologuard test Clinician Brochure or the Cologuard Plus test Clinician Brochure for additional information about the benefits and risks of using each version of the Cologuard product for CRC screening.
Rx only.